TheEdgeResearch
Home / Stocks / RXRX

Recursion Pharmaceuticals, Inc. (RXRX)

NASDAQ Healthcare Biotechnology
$3.30 ▼ -1.60%
Market Cap
$1.73B
Sector
Healthcare
Industry
Biotechnology
Beta
1.03
52-Wk Range
2.77-7.18
CEO
Najat Khan
Country
US
Currency
USD

Recursion Pharmaceuticals, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Salt Lake City, UT, US. The stock last traded at $3.30, down 1.60% on the session, giving a market capitalisation of $1.73B. On trailing twelve-month figures it carries a trailing P/E of -3.17, a net margin of -945.9%. Its beta of 1.03 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-3.17
Price / Sales
31.53
Price / Book
1.92
EV / EBITDA
-2.80
Gross margin
-46.7%
Operating margin
-991.7%
Net margin
-945.9%
Return on equity
Debt / equity
0.07
Current ratio
5.03
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
600
IPO date
2021-04-16
Headquarters
Salt Lake City, UT, US
About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.

Comparable companies

Recursion Pharmaceuticals, Inc. is most often compared with the following Healthcare names:

AGIOBEAMCOGTDNLIETNBGLPGIBRXLQDARCUSSRPT
More research on RXRX
RXRX technical analysis RXRX TheEdge Score Compare against peers
Open full interactive analysis & DCF →